[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"monoclonal-b-cell-lymphocytosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:monoclonal-b-cell-lymphocytosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,71,95,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":4,"leadSponsor":43,"locationsCount":46},"100127162","natural-history-study-of-monoclonal-b-cell-lymphocytosis-mbl-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-cllsll-lymphoplasmacytic-lymphoma-lplwaldenstrom-macroglobulinemia-wm-and-splenic-marginal-zone-lymphoma-smzl-100127162",false,"NCT00923507","Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL), Lymphoplasmacytic Lymphoma (LPL)\u002FWaldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)","-INCLUSION CRITERIA:\n\n1. Diagnosis of CLL\u002FSLL will be made according to the updated criteria of the NCI Working Group.\n\n   * on treatment or previously treated\n   * requiring or nearing first-line treatment\n\n   OR\n\n   Diagnosis of LPL\u002FWM. LPL is defined as the presence of an intertrabecular pattern of bone marrow infiltration by small lymphocytes showing plasmacytoid\u002Fplasma cell differentiation. WM, comprising \\>95% of LPL cases, describes the clinical syndrome of LPL associated with an IgM monoclonal gammopathy of any concentration. The remaining cases may be IgA, IgM, or non-secreting LPL. Immunophenotyping is required for diagnosis\n2. Age greater than or equal to 18 years.\n3. ECOG performance status of 0-2.\n4. Able to comprehend the investigational nature of the protocol and provide informed consent\n\nEXCLUSION CRITERIA:\n\n1\\. None","ALL","18 Years","110 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","Background\n\nThe development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia(CLL)\u002Fsmall lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)\u002FWaldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these methods in a natural history study can help identify processes involved in disease progression, and possibly lead to the discovery or validation of treatment targets.\n\nObjectives\n\nStudy the history of MBL\u002FCLL\u002FSLL\u002FLPL\u002FWM\u002FSMZL in patients prior to and after treatment. Characterize clinical, biologic and molecular events of disease stability and progression of patients enrolled on this protocol.\n\nEligibility:\n\n* Diagnosis of CLL\u002FSLL and on treatment\u002Fpreviously treated\u002Fnearing treatment\n* Diagnosis of LPL\u002FWM\n* As of February 5, 2025, patients with MBL and SMZL will no longer be enrolled.\n* Age greater than or equal to 18 years.\n* ECOG performance status of 0-2.\n\nDesign\n\nPatients are typically followed every 6 to 24 months in the clinic and have blood drawn. Patients may be asked to undergo additional testing, including bone marrow biopsy and aspiration, lymph node biopsy, positron emission tomography, and CT and MRI scans. Some of these tests (e.g., blood draw) may be required to monitor CLL\u002FSLL and LPL\u002FWM. Other tests (e.g., lymph node biopsy) may not be clinically indicated, but patients may be asked to undergo these procedures for research purposes.\n\nNo treatment will be administered on this study. If a patients requires treatment for their cancer, available NIH clinical trials and alternative treatment options will be discussed with the patient.\n\n...",[24,25,26,27,28],"Waldenstrom Macroglobulinemia","Lymphoplasmacytic Lymphoma","Monoclonal B-Cell Lymphocytosis","Small Lymphocytic Lymphoma","CLL (Chronic Lymphocytic Leukemia)",[30,31,32,33,34,35],"Chronic Lymphocytic Leukemia (CLL)","Monoclonal B Cell Lymphocytosis","Small Lymphocytic Lymphoma (SLL)","Natural History","Leukemia","Lymphoma","RECRUITING","2026-06-27",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":40},"2008-05-29",{"name":44,"class":45},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100557310","hematopoiesis-in-mbl-and-cll-versus-healthy-age-matched-control-subjects-100557310","NCT06536452","Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects","Hematopoiesis in Monoclonal B Cell Lymphocytosis (MBL) and B-Chronic Lymphocytic Leukemia (CLL) Versus Healthy Age-Matched Control Subjects","Inclusion Criteria:\n\n* Subjects in the CLL cohort who are eligible for these studies will have a clinically established diagnosis of CLL as assessed by flow cytometry and will include subjects who\n\n  * Remain untreated\n  * Are currently being treated\n  * Who have already been treated\n* Subjects in the MBL cohort will have a clinically established diagnosis of MBL\n* Healthy age-matched control subjects\n* Healthy younger control subjects aged \\> 40 years\n\nExclusion Criteria:\n\n* Anyone under 40\n* Healthy control subjects must not have a diagnosis of CLL or MBL",true,"40 Years",{"count":57,"type":20},50,"This study evaluates hematopoiesis to determine how MBL\u002FCLL affected bone marrow responds to fight off infections in the body.",[60,26],"Chronic Lymphocytic Leukemia","2026-03-26",{"date":63,"type":40},"2026-03-31",{"date":65,"type":40},"2016-11-18",{"date":67,"type":20},"2028-11-18",{"name":69,"class":70},"Mayo Clinic","OTHER",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":54,"sex":15,"minAge":16,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":46},"100104689","family-study-of-lymphoproliferative-disorders-100104689","NCT00626496","Family Study of Lymphoproliferative Disorders","Genetic Epidemiology of Lymphoproliferative Disorders","At least 2 living, blood related relatives, affected with a lymphoproliferative disorder.","100 Years",{"count":80,"type":20},3000,"Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic leukemia and non-Hodgkin lymphoma. Since there is evidence that these cancers cluster in families, this study aims to understand how genetics and environmental exposures contribute to the development of these cancers.",[83,84,85,26,86],"Lymphoma, Non-Hodgkin","Leukemia, Lymphocytic, Chronic, B-Cell","Lymphoma, B-Cell","Multiple Myeloma","2025-10-09",{"date":89,"type":40},"2025-10-14",{"date":91,"type":40},"2004-04-01",{"date":93,"type":20},"2029-12-31",{"name":69,"class":70},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":54,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":105,"conditions":106,"keywords":114,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100548075","risk-and-clinical-consequences-of-low-count-monoclonal-b-cell-lymphocytosis-lc-mbl-100548075","NCT06416267","Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)","Immune Biomarkers, Genetic Risk, and the Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)","MBL RiskConseq","Inclusion Criteria:\n\n* Individuals over the age pf 40\n\nExclusion Criteria:\n\n* Individuals with lymphoproliferative disorder",{"count":104,"type":20},1500,"The aim of this proposal is to identify immune biomarkers, genetic risk, and the clinical consequences of low count monoclonal B-cell lymphocytosis (LC MBL), a common premalignant condition affecting up to 17% of European adults age\\>40. LC MBL is a precursor to chronic lymphocytic leukemia (CLL), characterized by a circulating population of clonal B-cells. It is relatively understudied, despite emerging evidence of clinical consequences such as increased risk for life-threatening infections and lymphoid malignancies. Studies reported that male sex, age, family history of CLL, and CLL-susceptibility genetic loci were associated with LC MBL risk. These findings were reported in European ancestry individuals and have not been generalized to other thnicities. This study will provide this missing knowledge using a unique multi-ethnic Israeli population of Jews and Arabs that have one of the highest and lowest age-standardized incidence rates of CLL in the world, respectively, and characterized with different genetic backgrounds.",[26,60,107,108,109,110,111,112,113],"Infections","Cancers","Cardiovascular Diseases","Alzheimer Disease","Dementia","Autoimmune Diseases","Parkinson Disease",[115,116,117,107,108,118],"Monoclonal B cell Lymphocytosis","Genetic Risk","Outcomes","CLL","NOT_YET_RECRUITING","2024-05-10",{"date":122,"type":40},"2024-05-16",{"date":124,"type":20},"2024-08",{"date":126,"type":20},"2040-12",{"name":128,"class":70},"University of Haifa",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":54,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":137,"targetDuration":138,"studyType":21,"phases":4,"briefSummary":139,"conditions":140,"keywords":143,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":4},"100494500","familial-b-cell-lymphoproliferative-disorders-100494500","NCT05718986","Familial B-cell Lymphoproliferative Disorders","Epidemiology of Familial B-cell Lymphoproliferative Disorders","Familial_LPD","Inclusion Criteria:\n\n* Patient inclusion criteria:\n\nPatients must have LPD and must have a family history of LPD. LPD patients who signed an informed consent to participate in the study.\n\nCriteria for the inclusion of relatives of patients:\n\nRelatives must be related by blood to LPD patients or unrelated (for control group).\n\nRelatives who signed an informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant women, special populations and those lacking judgment will not be included",{"count":19,"type":20},"15 Years","This study investigates families with at least two cases of B-cell lymphoproliferative disorders (LPD), and evaluates the prevalence of LPD in families, the relationship between medical history, genetic factors, and the risk of familial LPD, and various clinical outcomes for these families in a multiethnic population of Jews and Arabs in Israel.",[141,142,26,60],"Lymphoproliferative Disorders","Premalignant",[144,60,145],"lymphoproliferative disorders","Monoclonal B-cell Lymphocytosis","2024-05-07",{"date":148,"type":40},"2024-05-08",{"date":150,"type":20},"2024-06",{"date":126,"type":20},{"name":128,"class":70}]